[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351928-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351928-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zdhhc17-mediated-cdk4-palmitoylation-drives-cell-cycle-progression-and-orchestrates-cancer-immune-surveillance","ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance","","Uncontrolled cell cycle progression is a hallmark of cancer, governed by intrinsic and extrinsic stimuli, yet the role of fatty acids—especially palmitic acid—in cell cycle regulation is not fully resolved. This study shows that blocking protein palmitoylation with 2-bromohexadecanoic acid or depleting ZDHHC17 causes profound cell cycle arrest. ZDHHC17 palmitoylates CDK4 to promote cyclin D1 interaction through TRAF6-mediated K11-linked ubiquitination, reducing CDK4 kinase activity and tumor growth. In HFD-fed mouse models, Zdhhc17 loss diminishes cell cycle progression and immune response, while clinical ZDHHC17 correlates with anti-PD-1 non-response via CDK4-mediated PD-L1 repression, supporting CDK4 inhibitor plus immune checkpoint blockade strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/zdhhc17-mediated-cdk4-palmitoylation-drives-cell-cycle-progression-and-orchestrates-cancer-immune-surveillance/351928/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zdhhc17-mediated-cdk4-palmitoylation-drives-cell-cycle-progression-and-orchestrates-cancer-immune-surveillance/351928.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does ZDHHC17 affect cell cycle progression in the study?","Question",{"text":63,"@type":64},"Inhibition of protein palmitoylation or depletion of ZDHHC17 leads to profound cell cycle arrest. Mechanistically, ZDHHC17 palmitoylates CDK4, enabling downstream activation and progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What molecular mechanism links ZDHHC17 to CDK4 activity?",{"text":68,"@type":64},"ZDHHC17-mediated palmitoylation facilitates CDK4 interaction with cyclin D1 (CCND1). This process depends on TRAF6-mediated K11-linked ubiquitination of CDK4, and blockade reduces CDK4 kinase activity.",{"name":70,"@type":61,"acceptedAnswer":71},"Why might high ZDHHC17 predict poor response to anti-PD-1 therapy?",{"text":72,"@type":64},"High ZDHHC17 expression is positively correlated with non-response to anti-PD-1 therapies. The study links this to CDK4-mediated repression of PD-L1, and proposes combining CDK4 inhibitors with immune checkpoint blockers to overcome ZDHHC17-driven cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351928,1790359602,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Advanced Science  \n| [www.advancedscience.com](www.advancedscience.com)\u003Cbr> RESEARCH ARTICLE \u003Cbr>ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance\u003Cbr>Zekang Wang1  Peipei Song2  Xueji Wu2  Lei Wang2  Wei Xie2  Pinning Feng3   Chao Cheng1   Jianping Guo2 \u003Cbr>1 Center of Thoracic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China  2Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China  3 Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China\u003Cbr>Correspondence: Pinning Feng ([fengpn@mail.sysu.edu.cn](fengpn@mail.sysu.edu.cn))  Chao Cheng (chengch3@mail.sysu.edu.cn)  Jianping Guo (guojp6@mail.sysu.edu.cn)\u003Cbr>Received: 6 March 2026  Revised: 30 April 2026  Accepted: 7 May 2026\u003Cbr>Keywords: CDK4 | cell cycle | immunotherapy | palmitoylation | ZDHHC17\u003Cbr>\u003Cbr>ABSTRACT\u003Cbr>Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic and extrinsic stimuli. However, the role of fatty acids, in particular palmitic acid, in cell cycle control remains incompletely understood. Here, we observe that inhibition of protein palmitoylation by administrating 2-bromohexadecanoic acid (2-BP) or depleting ZDHHC17, leads to profound cell cycle arrest. Mechanistically, ZDHHC17 palmitoylates CDK4, thereby facilitating its interaction with cyclin D1 (encoded by CCND1), a process depending on TRAF6-mediated K11-linked ubiquitination ofCDK4. While, blockade of either palmitoylation or ubiquitination markedly reduces CDK4 kinase activity, resulting in cell cycle arrest and suppressed tumor growth. Furthermore, Zdhhc17-depletion displays reduced cell cycle progression and immune response in a high fat diet (HFD)-feeding mouse model. Clinically, high ZDHHC17 expression is positively correlated with non-response to anti-PD-1 therapies in cancer patients, partially due to CDK4-mediated repression of PD-L1 . Thereby, we propose a rational combination strategy of employing CDK4 inhibitors with immune checkpoint blockers (ICBs) to overcome ZDHHC17-driven cancers. In sum, our study uncovers a novel cell cycle control mechanism by ZDHHC17-mediated palmitoylation and TRAF6-mediated ubiquitination of CDK4, presenting a potential therapeutic avenue by targeting the ZDHHC17-TRAF6-CDK4 axis for cell cycle dysregulated cancers.\u003Cbr>|  |\n| --- | --- |\n| 1  Introduction\u003Cbr>Uncontrolled cell cycle progression is a hallmark of cancer [1] . Consequently, systematic treatments such as chemotherapy (e.g., taxol) and small-molecule inhibitors by targeting the cell cycle have been extensively explored and approved for various cancer therapies as the first-in-class drugs [2] . Of note, CDK4/6 inhibitors, such as Palbociclib (Pal) and Abemaciclib (Abe), have shown efficacy in treating hormone receptor (HR) positive breast cancer [3, 4] . However, both intrinsic and acquired resis- | tance to CDK4/6 inhibitors have emerged, driven by feedback regulation or crosstalk with other signaling pathways [5] . To overcome these challenges, combination therapies by incorporating CDK inhibitors with other targeted agents, such as PI3K/AKT inhibitors [6], BRD inhibitors [7], or hormone inhibitors [8], have been accumulating developed. More recently, CDK4/6 inhibitors have been found to significantly enhance immunotherapeutic responses, partially by promoting PD-L1 expression in tumor cells [9] or inducing cytokine secretion that modulates the tumor microenvironment (TME) [10] . As a result, combining CDK4 |\n| Zekang Wang and Peipei Song contributed equally to this work. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Advanced Science published by Wiley-VCH GmbH |  |\n\n","cbCaieUXQJQJOz2q","https://ap.wps.com/l/cbCaieUXQJQJOz2q","pdf",6156652,"English","# Introduction\n## CDK4/6 inhibitors and resistance\n## CDK regulation and checkpoint control\n## Metabolism, palmitic acid, and protein palmitoylation in cell cycle","[{\"question\":\"How does ZDHHC17 affect cell cycle progression in the study?\",\"answer\":\"Inhibition of protein palmitoylation or depletion of ZDHHC17 leads to profound cell cycle arrest. Mechanistically, ZDHHC17 palmitoylates CDK4, enabling downstream activation and progression.\"},{\"question\":\"What molecular mechanism links ZDHHC17 to CDK4 activity?\",\"answer\":\"ZDHHC17-mediated palmitoylation facilitates CDK4 interaction with cyclin D1 (CCND1). This process depends on TRAF6-mediated K11-linked ubiquitination of CDK4, and blockade reduces CDK4 kinase activity.\"},{\"question\":\"Why might high ZDHHC17 predict poor response to anti-PD-1 therapy?\",\"answer\":\"High ZDHHC17 expression is positively correlated with non-response to anti-PD-1 therapies. The study links this to CDK4-mediated repression of PD-L1, and proposes combining CDK4 inhibitors with immune checkpoint blockers to overcome ZDHHC17-driven cancers.\"}]","ZDHHC17-Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance | PDF",1790096527,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bbd956537a4ab07385a0d2808ab7bcf.webp",983,1283,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba2c47475eb4839315745c960e95c235.webp",982,1281,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b58d0887732dc3a8992a65686df9f85b.webp",981,1280,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0b071ee59d074c728a24ed6b628b856.webp",980,1279]